LIVER DISEASES THERAPEUTICS MARKET ANALYSIS

Liver Diseases Therapeutics Market, Therapy Type (Anti-Rejection Drugs/Immunosuppressant’s, Chemotherapy Drugs, Targeted therapy, Vaccines, Anti-Viral Drugs, Immunoglobulin’s, Corticosteroids), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2023
Code : CMI3809
Pages :165
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Liver Diseases Therapeutics Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global liver diseases therapeutics market over the forecast period. This is due to the approval of newer combination therapies for the treatment of liver diseases by the U.S. FDA. For instance, on October 24, 2022, U.S. FDA approved a new immunotherapy combination for the treatment of hepatocellular carcinoma, the most common type of liver cancer. This combination consists of a single dose of tremelimumab (Imjudo) followed by treatment with durvalumab (Imfinzi) in a Single Tremelimumab Regular Interval Durvalumab (STRID) regimen.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa